Phosphodiesterase type 5 inhibitors for the management of erectile dysfunction: Preference and adherence to treatment

Current Pharmaceutical Design

Volumn 15, Issue 30, 2009, Pages 3486-3495

  Al Shaiji, T F ^a   Brock, G B ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Adherence; Cost; Education; PDE5 inhibitors; Preference; Treatment expectations; Treatment optimization

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; VARDENAFIL;

CLINICAL TRIAL; DIZZINESS; DOSE RESPONSE; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG PREFERENCE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EDUCATION; ERECTILE DYSFUNCTION; FLUSHING; HUMAN; LEG CRAMP; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PERSONAL NEEDS; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RHINITIS; RISK FACTOR; SEXUAL BEHAVIOR; SIDE EFFECT; SOCIAL PSYCHOLOGY;

CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; ERECTILE DYSFUNCTION; HUMANS; MALE; PATIENT COMPLIANCE; PATIENT EDUCATION AS TOPIC; PATIENT SATISFACTION; PHOSPHODIESTERASE INHIBITORS;

EID: 70449448974     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209789206944     Document Type: Review

References (79)

1. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993; 270: 83-90.
2. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61. (Pubitemid 24046934)
3. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84: 50-56
4. Hatzimouratidis K, Hatzichristou DG. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? Drugs 2005; 65: 1621-1650
5. Derby CA, Mohr BA, Goldstein I, Feldman HA, Johannes CB, McKinlay JB. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology 2000; 56: 302-306
6. Wagner G, Fugl-Meyer KS, Fugl-Meyer AR. Impact of erectile dysfunction on quality of life: patient and partner perspectives. Int J Impot Res 2000; 12 (Suppl 4): S144-6. (Pubitemid 30777470)
7. Brock G, Chan J, Carrier S, Chan M, Salgado L, Klein AH, et al. The treatment of erectile dysfunction study: focus on treatment satisfaction of patients and partners. BJU Int 2007; 99: 376-382 (Pubitemid 46103120)
8. Nicolosi A, Moreira ED, Jr., Villa M, Glasser DB. A population study of the association between sexual function, sexual satisfaction and depressive symptoms in men. J Affect Disord 2004; 82: 235-243 (Pubitemid 39370825)
9. Strand J, Wise TN, Fagan PJ, Schmidt CW, Jr. Erectile dysfunction and depression: category or dimension? J Sex Marital Ther 2002; 28: 175-181
10. Kostis JB, Jackson G, Rosen R, Barrett-Connor E, Billups K, Burnett AL, et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005; 96: 85M-93M. (Pubitemid 43017226)
11. Giannitsas K, Konstantinopoulos A, Patsialas C, Perimenis P. Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction. Patient Prefer Adher 2008; 2: 149-155.
12. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998; 338: 1397-1404
13. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168: 1332-1336 (Pubitemid 35034115)
14. Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002; 23: 763-771 (Pubitemid 36300965)
15. Ljunggren C, Hedelin H, Salomonsson K, Stroberg P. Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance. J Sex Med 2008; 5: 469-475 (Pubitemid 351167755)
16. Hackett GI. Patient preferences in treatment of erectile dysfunction: the continuing importance of patient education. Clin Cornerstone 2005; 7: 57-65.
17. Rosen RC, Fisher WA, Eardley I, Niederberger C, Nadel A, Sand M. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004; 20: 607-617
18. Montorsi F, Salonia A, Briganti A, Barbieri L, Zanni G, Suardi N, et al. Vardenafil for the treatment of erectile dysfunction: a critical review of the literature based on personal clinical experience. Eur Urol 2005; 47: 612-621 (Pubitemid 40521906)
19. Skoumal R, Chen J, Kula K, Breza J, Calomfirescu N, Basson BR, et al. Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction. Eur Urol 2004; 46: 362-9; discussion 369.
20. Ashworth M, Clement S, Wright M. Demand, appropriateness and prescribing of 'lifestyle drugs': a consultation survey in general practice. Fam Pract 2002; 19: 236-241
21. Stiggelbout AM, de Haes JC. Patient preference for cancer therapy: an overview of measurement approaches. J Clin Oncol 2001; 19: 220-230
22. Eardley I, Montorsi F, Jackson G, Mirone V, Chan ML, Loughney K, et al. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study. BJU Int 2007; 100: 122-129 (Pubitemid 46878565)
23. Mulhall JP. Understanding erectile dysfunction medication preference studies. Curr Opin Urol 2004; 14: 367-373 (Pubitemid 39506931)
24. Mulhall JP, Montorsi F. Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction. Eur Urol 2006; 49: 30-37 (Pubitemid 41789951)
25. Govier F, Potempa AJ, Kaufman J, Denne J, Kovalenko P, Ahuja S. A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction. Clin Ther 2003; 25: 2709-2723 (Pubitemid 37510585)
26. Eardley I, Mirone V, Montorsi F, Ralph D, Kell P, Warner MR, et al. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy. BJU Int 2005; 96: 1323-1332 (Pubitemid 41743933)
27. Dean J, Hackett GI, Gentile V, Pirozzi-Farina F, Rosen RC, Zhao Y, et al. Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study. J Sex Med 2006; 3: 650-661 (Pubitemid 43919019)
28. von Keitz A, Rajfer J, Segal S, Murphy A, Denne J, Costigan T, et al. A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. Eur Urol 2004; 45: 499-507; discussion 507-509 (Pubitemid 38376216)
29. Lee J, Pommerville P, Brock G, Gagnon R, Mehta P, Krisdaphongs M, et al. Physician-rated patient preference and patient- and partner-rated preference for tadalafil or sildenafil citrate: results from the Canadian 'Treatment of Erectile Dysfunction' observational study. BJU Int 2006; 98: 623-629
30. Tolra JR, Campana JM, Ciutat LF, Miranda EF. Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. J Sex Med 2006; 3: 901-909
31. Stroberg P, Ljunggren C, Hedelin H. Patient peference in clinical practice in treatment of erectile dysfunction with PDE-5 inhibitors. J Sex Med 2004; 1(Suppl 1): 41.
32. Claes HIM, Van Poppel H. The use of sildenafil, tadalafil and vardenafil in clinical practice. J Sex Med 2004; 1: 42.
33. Pakh NC, Park HJ, Nam JK, Kim JM. Efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil: Results of open label study of patient preference in Korea. J Sex Med 2005; 2:35.
34. Porst H, Keingarn M, Arnos E. The three PDE-5 inhibitors sildenafil, tadalafil and vardenafil. Results of a comparative preference trial in 222 patients with erectile dysfunction. J Urol 2004; 171: 315.
35. Sommer F, Mathers M, Klotz T, Bondarenko B, Caspers HP, Engelmann V. Which PDE-5 inhibitors do patients prefer? A comparative study of 50 mg Sildenafil, 10 mg Tadalafil and 10 mg Vardenafil. Eur Urol Suppl 2004; 3: 105.
36. Seftel AD. Challenges in oral therapy for erectile dysfunction. J Androl 2002; 23: 729-736 (Pubitemid 36300960)
37. Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 2003; 61: 8-14. (Pubitemid 36349124)
38. Padma-nathan H, Eardley I, Kloner RA, Laties AM, Montorsi F. A 4-year update on the safety of sildenafil citrate (Viagra). Urology 2002; 60: 67-90. (Pubitemid 35303364)
39. Mulhall JP, McLaughlin TP, Harnett JP, Scott B, Burhani S, Russell D. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction. J Sex Med 2005; 2: 848-855 (Pubitemid 41727398)
40. Jarow JP, Burnett AL, Geringer AM. Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J Urol 1999; 162: 722-725
41. Jiann BP, Yu CC, Su CC, Tsai JY. Compliance of sildenafil treatment for erectile dysfunction and factors affecting it. Int J Impot Res 2006; 18: 146-149 (Pubitemid 43336479)
42. Klotz T, Mathers M, Klotz R, Sommer F. Why do patients with erectile dysfunction abandon effective therapy with sildenafil (Viagra)? Int J Impot Res 2005; 17: 2-4. (Pubitemid 40299986)
43. Son H, Park K, Kim SW, Paick JS. Reasons for discontinuation of sildenafil citrate after successful restoration of erectile function. Asian J Androl 2004; 6: 117-120 (Pubitemid 38780013)
44. Souverein PC, Egberts AC, Meuleman EJ, Urquhart J, Leufkens HG. Incidence and determinants of sildenafil (dis)continuation: the Dutch cohort of sildenafil users. Int J Impot Res 2002; 14: 259-265 (Pubitemid 34947730)
45. Hatzichristou D, Haro JM, Martin-Morales A, von Keitz A, Riley A, Bertsch J, et al. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study. Int J Clin Pract 2007; 61: 1850-1862 (Pubitemid 47573096)
46. Taylor H, Leitman R. Men with erectile dysfunction (ED) want improved relations wtth their partners. Harris Interact Health Care News 2001; 1: 1-4.
47. Hanson-Divers C, Jackson SE, Lue TF, Crawford SY, Rosen RC. Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol 1998; 159: 1541-1547 (Pubitemid 29117337)
48. Stroberg P, Murphy A, Costigan T. Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference. Clin Ther 2003; 25: 2724-2737 (Pubitemid 37510586)
49. Marwick C. Survey says patients expect little physician help on sex. JAMA 1999; 281: 2173-4.
50. Hackett GI. What do patients expect from erectile dysfunction therapy? Eur Urol Suppl 2002; 1: 4-11.
51. Stroberg P, Ljunggren CRN, Hedelin H. Patient preference in clinical practice in treatment of erectile dysfunction with PDE- 5 inhibitors. J Sex Med 2004; 1: 41.
52. Cappelleri JC, Bell SS, Althof SE, Siegel RL, Stecher VJ. Comparison between sildenafil-treated subjects with erectile dysfunction and control subjects on the Self-Esteem And Relationship questionnaire. J Sex Med 2006; 3: 274-282
53. Albaugh J, Amargo I, Capelson R, Flaherty E, Forest C, Goldstein I, et al. Health care clinicians in sexual health medicine: focus on erectile dysfunction. Urol Nurs 2002; 22: 217-31; quiz 232.
54. Lue TF, Giuliano F, Montorsi F, Rosen RC, Andersson KE, Althof S, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2004; 1: 6-23. (Pubitemid 40424662)
55. Dean J, Rubio-Aurioles E, McCabe M, Eardley I, Speakman M, Buvat J, et al. Integrating partners into erectile dysfunction treatment: improving the sexual experience for the couple. Int J Clin Pract 2008; 62: 127-133 (Pubitemid 350294024)
56. McCullough AR, Barada JH, Fawzy A, Guay AT, Hatzichristou D. Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology 2002; 60: 28-38. (Pubitemid 35300144)
57. Riley A. The role of the partner in erectile dysfunction and its treatment. Int J Impot Res 2002; 14 (Suppl 1): S105-9.
58. Colson MH. [Women faced with the problem of erectile dysfunction: women's view on a male problem]. Prog Urol 2005;15: 710-716
59. Montorsi F, Althof SE. Partner responses to sildenafil citrate (Viagra) treatment of erectile dysfunction. Urology 2004; 63: 762-767 (Pubitemid 38479426)
60. Fisher W, Meryn S, Sand M, Brandenburg U, Buvat J, Mendive J, et al. Communication about erectile dysfunction among men with ED, partners of men with ED, and physicians: the Strike Up a Conversation study-Part I. J Men's Health Gend 2005; 2: 64-78. (Pubitemid 41095294)
61. Fisher WA, Rosen RC, Mollen M, Brock G, Karlin G, Pommerville P, et al. Improving the sexual quality of life of couples affected by erectile dysfunction: a double-blind, randomized, placebo-controlled trial of vardenafil. J Sex Med 2005; 2: 699-708. (Pubitemid 41742930)
62. Fugl-Meyer K, Fugl-Meyer AR. Sexual disabilities are not singularities. Int J Impot Res 2002; 14: 487-493 (Pubitemid 36068426)
63. Chevret M, Jaudinot E, Sullivan K, Marrel A, De Gendre AS. Quality of sexual life and satisfaction in female partners of men with ED: psychometric validation of the Index of Sexual Life (ISL) questionnaire. J Sex Marital Ther 2004; 30: 141-155 (Pubitemid 38470794)
64. Blumel JE, Castelo-Branco C, Cancelo MJ, Romero H, Aprikian D, Sarra S. Impairment of sexual activity in middle-aged women in Chile. Menopause 2004; 11: 78-81. (Pubitemid 40362202)
65. Ichikawa T, Takao A, Manabe D, Saegusa M, Tanimoto R, Aramaki K, et al. The female partner's satisfaction with sildenafil citrate treatment of erectile dysfunction. Int J Urol 2004; 11: 755-762 (Pubitemid 39387523)
66. Conaglen HM, Conaglen JV. Investigating women's preference for sildenafil or tadalafil use by their partners with erectile dysfunction: the partners' preference study. J Sex Med 2008; 5: 1198-1207
67. Goldstein I, Fisher WA, Sand M, Rosen RC, Mollen M, Brock G, et al. Women's sexual function improves when partners are administered vardenafil for erectile dysfunction: a prospective, randomized, double-blind, placebo-controlled trial. J Sex Med 2005; 2: 819-832 (Pubitemid 41727394)
68. Althof SE, Seftel AD. The evaluation and management of erectile dysfunction. Psychiatr Clin North Am 1995; 18: 171-192
69. Jiann BP, Yu CC, Su CC, Huang JK. Rechallenge prior sildenafil nonresponders. Int J Impot Res 2004; 16: 64-68
70. Atiemo HO, Szostak MJ, Sklar GN. Salvage of sildenafil failures referred from primary care physicians. J Urol 2003; 170: 2356-2358
71. Hatzichristou D, Moysidis K, Apostolidis A, Bekos A, Tzortzis V, Hatzimouratidis K, et al. Sildenafil failures may be due to inadequate patient instructions and follow-up: a study on 100 nonresponders. Eur Urol 2005; 47: 518-22; discussion 522-523
72. Barada J. Salvage of "sildenafil (viagra) failures": benefits of patient and retreatment with sildenafil. Int J Impot Res 2001; 13: S49.
73. Brock G, Carrier S, Casey R, Tarride JE, Elliott S, Dugre H, et al. Can an educational program optimize PDE5i therapy? A study of Canadian primary care practices. J Sex Med 2007; 4: 1404-1413 (Pubitemid 47337688)
74. Desvaux P, Corman A, Hamidi K, Pinton P. [Management of erectile dysfunction in daily practice - PISTES study]. Prog Urol 2004; 14: 512-520
75. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Impot Res 2000; 12: 305-311
76. Stroberg P, Hedelin H, Bergstrom A. Is sex only for the healthy and wealthy? J Sex Med 2007; 4: 176-182
77. Aversa A, Caprio M, Rosano GM, Spera G. Endothelial effects of drugs designed to treat erectile dysfunction. Curr Pharm Des 2008; 14(35): 3768-3778
78. Caprio M, Mammi C, Jaffe IZ, Zennaro MC, Aversa A, Mendelsohn ME, et al. The mineralocorticoid receptor in endothelial physiology and disease: novel concepts in the understanding of erectile dysfunction. Curr Pharm Des 2008; 14(35): 3749-3757
79. Potenza MA, Montagnani M. Abnormal insulin signaling: early detection of silent coronary artery disease-erectile dysfunction? Curr Pharm Des 2008; 14(35): 3737-3748